Lexaria Bioscience

Lexaria Bioscience Corp’s (NASDAQ:LEXX, LEXXW) proprietary medication delivery technology, DehydraTECH™, improves the way bioactive compounds enter the bloodstream by promoting healthier delivery methods and increasing the effectiveness of fat-soluble active molecules.

DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver active ingredients more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and many patents pending worldwide.

Lexaria’s technology is an additional process incorporated into the formulation and manufacturing process of existing or new orally ingestible and topical products. This step involves mixing the active ingredient as a delivery “payload” together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level, before integrating the newly combined molecules into end-product production across a range of dosage form factors.

(NASDAQ: LEXX, LEXXW)

PROVEN ORAL DELIVERY TECHNOLOGY FOR
WEIGHT LOSS, DIABETES, & MORE

Receive Investor Kit:

ABOUT LEXARIA BIOSCIENCE

DehydraTECH™ Benefits

Patented DehydraTECH Process

Lexaria's Molecular Integration Process